Blafarm, I posted a while back the following -

Cytodyn, with so many indications to work on, should set up a bunch of wholly owned companies to each take on a few indications and let them run with them. I envision it like partnerships.

This is just a wild stab at a structure that would delegate tasks and responsibilities to talented teams. It makes sense to me but that is one way to get to the big end of the funnel without getting spread too thin and being distracted.

I liked this model because I thought it made compensation issues pretty clear and easy too. Everything is not in one big wad, demanding direction from the top - too top centric.


I do think the present management team is capable of delegating tasks to talented people of the caliber of the people on the Scientific Advisory Committee to run these partnership, wholly owned companies.

If Vyera is somehow an obstacle to other ways of organizing the testing, approving and marketing of Leronlimab for other indications, perhaps this structure will work.